[ad_1]
SÃO PAULO – A vaccine that protects against the four subtypes of the dengue virus can begin to be produced until December 2019 in Brazil. On Wednesday, the Butantan Institute of São Paulo signed a partnership with the US pharmaceutical group MSD to enable faster development of the food.
This agreement was made possible by studies conducted by Butantan for the production is more advanced than in the foreign laboratory. "We are already in the third phase of clinical development, during which the vaccine is tested on humans," said Dimas Tadeu Covas, director of the Institute
. The partnership provides for a maximum contribution of R $ 101 million to the lab, which will be released as testing progresses. "The MSD has ceded the rights of the US National Institute of Health to the Butantan Institute, which is why we are funding studies in Brazil and the two institutes will level the development of the vaccine," said Mike Nally, director of the vaccination sector at the American laboratory.
the completion of the Phase III clinical trial, the next step will be to register the tetravalent vaccine with the National Health Surveillance Agency (Anvisa). "This does not mean that it is already available to the entire population because it remains the process of government authorization and purchase and that is not guaranteed quickly ", commented Covas
. According to the director, during the vaccination Soon, MDS will be able to market its products with the rest of the world, while Butantã will trade with Brazil. "The vaccination rate will be over 80% for people of all ages who have contracted dengue fever, and the return could reach $ 1.5 billion for Butantan," he said.
* A journalist went to the invitation of MSD
See more:
This is not just a treatment; SUS also controls endemic, produces vaccines and trains doctors
The discovery of zika in monkeys launches an alert on possible epidemics
[ad_2]
Source link
